MediWound (NASDAQ:MDWD) Stock Passes Above Fifty Day Moving Average of $12.30

MediWound Ltd. (NASDAQ:MDWD – Get Rating) shares passed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $12.30 and traded as high as $13.85. MediWound shares last traded at $13.56, with a volume of 65,818 shares traded.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. Cowen lifted their price objective on shares of MediWound from $6.00 to $25.00 and gave the stock an “outperform” rating in a research note on Friday, December 30th. Maxim Group began coverage on shares of MediWound in a research note on Thursday, December 22nd. They issued a “buy” rating on the stock. HC Wainwright lifted their target price on shares of MediWound from $5.50 to $23.00 and gave the stock a “buy” rating in a research report on Wednesday, January 4th. Finally, StockNews.com began coverage on shares of MediWound in a research report on Friday, December 23rd. They issued a “sell” rating on the stock. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $40.40.

MediWound Stock Up 5.2 %

The firm’s 50-day moving average price is $12.30 and its two-hundred day moving average price is $11.99. The firm has a market capitalization of $78.93 million, a PE ratio of -3.66 and a beta of 0.99.

MediWound (NASDAQ:MDWD – Get Rating) last posted its quarterly earnings results on Tuesday, November 15th. The biopharmaceutical company reported ($0.91) EPS for the quarter, missing the consensus estimate of ($0.70) by ($0.21). The company had revenue of $5.80 million for the quarter, compared to analyst estimates of $4.65 million. Equities research analysts forecast that MediWound Ltd. will post -2.71 EPS for the current year.

Institutional Trading of MediWound

Institutional investors have recently made changes to their positions in the stock. Essex Investment Management Co. LLC acquired a new stake in shares of MediWound during the third quarter worth approximately $405,000. Renaissance Technologies LLC lifted its stake in MediWound by 3.8% in the second quarter. Renaissance Technologies LLC now owns 475,422 shares of the biopharmaceutical company’s stock valued at $875,000 after acquiring an additional 17,600 shares during the last quarter. Sargent Investment Group LLC lifted its stake in MediWound by 40.0% in the second quarter. Sargent Investment Group LLC now owns 524,750 shares of the biopharmaceutical company’s stock valued at $966,000 after acquiring an additional 150,000 shares during the last quarter. Altium Capital Management LP acquired a new stake in MediWound in the third quarter valued at approximately $1,775,000. Finally, Armistice Capital LLC acquired a new stake in MediWound in the third quarter valued at approximately $2,663,000. 13.58% of the stock is currently owned by institutional investors and hedge funds.

MediWound Company Profile

(Get Rating)

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.